- Conditions
- Schizophrenia
- Interventions
- Bifeprunox, Quetiapine
- Drug
- Lead sponsor
- Solvay Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 69
- States / cities
- Anaheim, California • Cerritos, California • Costa Mesa, California + 52 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 29,129
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Overweight, Obesity
- Interventions
- Zenagamtide, Semaglutide, Placebo (matched to semaglutide), Placebo (matched to zenagamtide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 45
- States / cities
- Lancaster, California • Palm Springs, California • Pomona, California + 40 more
- Conditions
- Medulloblastoma, Neuroectodermal Tumor
- Interventions
- TTRNA-xALT, TTRNA-DCs
- Biological
- Lead sponsor
- University of Florida
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2025
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Gainesville, Florida
- Conditions
- Multiple Sclerosis
- Interventions
- Ocrelizumab
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Interaction
- Interventions
- Cannabidiol in the form of hemp, Clopidogrel
- Drug
- Lead sponsor
- Washington State University
- Other
- Eligibility
- 21 Years to 64 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Spokane, Washington
- Conditions
- Solid Tumor, HNSCC, RCC, CRC
- Interventions
- SPX- 303 Injection, a bispecific anti-LILRB2 / anti-PD-L1 Antibody
- Biological
- Lead sponsor
- SparX Biotech(Jiangsu) Co., Ltd.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- repaglinide, metformin, repaglinide and metformin combination tablet
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
- Interventions
- Ibrutinib, MEDI4736
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Duarte, California • Stanford, California + 8 more
- Conditions
- Pain
- Interventions
- Bupivacaine, Clonidine, Morphine
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 4 Years to 16 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Neoplasms, Breast
- Interventions
- Immunotherapeutic SB719125 (Primary)
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years to 70 Years · Female only
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 4
- States / cities
- Boca Raton, Florida • Buffalo, New York • Charlotte, North Carolina + 1 more
- Conditions
- Glucose Transporter Type 1 Deficiency Syndrome, Glut1 Deficiency Syndrome
- Interventions
- Triheptanoin
- Drug
- Lead sponsor
- Juan Pascual
- Other
- Eligibility
- 30 Months to 55 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Late-onset Sepsis
- Interventions
- Ceftaroline Fosamil, Ampicillin, Aminoglycoside
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 7 Days to 59 Days
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Advanced Solid Tumors, Malignant Neoplasm
- Interventions
- MK-2010, Sacituzumab tirumotecan, Histamine H1 Receptor Antagonist, Histamine H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid mouthwash (dexamethasone or equivalent), Epinephrine
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Solid Tumor, Adult, Oncology
- Interventions
- TRE-515
- Drug
- Lead sponsor
- Trethera
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 2
- States / cities
- Santa Monica, California • Huntersville, North Carolina
- Conditions
- Sunscreening Agent
- Interventions
- Coppertone (BAY 987517)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Union, New Jersey
- Conditions
- HIV Infections
- Interventions
- Sulfamethoxazole-Trimethoprim, Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1990
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Hepatic Impairment
- Interventions
- belapectin
- Drug
- Lead sponsor
- Galectin Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 4
- States / cities
- Rialto, California • Miami, Florida • San Antonio, Texas
- Conditions
- Autism
- Interventions
- Memantine - Extended Release (ER), Placebo
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Sacramento, California • San Francisco, California + 14 more
- Conditions
- Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
- Interventions
- Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab, Placebo Saline Infusion, Docetaxel
- Biological · Other · Drug
- Lead sponsor
- CatalYm GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Los Angeles, California • Mineola, New York + 2 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- BMS-986165, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 363 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • El Cajon, California + 45 more
- Conditions
- Hypertension
- Interventions
- candesartan cilexetil (Atacand)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 1 Year to 6 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 13 more
- Conditions
- Depressive Disorder, Major
- Interventions
- LY2216684, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 495 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 16 more
- Conditions
- Cannabidiol Effects, Driving Performance
- Interventions
- Cannabidiol (CBD) Oil 300mg, Cannabidiol (CBD) Oil 150mg, Placebo Oil
- Drug
- Lead sponsor
- West Virginia University
- Other
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Hodgkin Lymphoma
- Interventions
- Involved site radiotherapy, Doxorubicin, Bleomycin, Brentuximab vedotin, Vinblastine, Dacarbazine, Haematopoietic growth factor
- Radiation · Drug
- Lead sponsor
- University College, London
- Other
- Eligibility
- 16 Years to 69 Years
- Enrollment
- 1,042 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 3
- States / cities
- Stanford, California • Miami, Florida • New York, New York